Drug Profile
Myc 102
Alternative Names: Myc102; MycobactovirLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator LTN Pharm; TGV-Laboratories
- Developer LTN Pharm; National Institutes of Health (USA); TGV-Laboratories; University of Texas Health Science Center at San Antonio
- Class Antifungals; Small molecules
- Mechanism of Action Chitin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dermatomycoses; Mycoses; Vulvovaginal candidiasis
- Phase II Gingivitis; Periodontitis
- No development reported Aspergillosis; Candidiasis; Cryptococcosis; Onychomycosis; Pneumonia
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Candidiasis in USA (Vaginal, Pessary)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Dermatomycoses in USA (Topical, Cream)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Gingivitis in USA (Buccal, Liquid)